TRANSGENE (EPA:TNG) | Finanzwire

BRIEF

published on 04/10/2025 at 20:20, 6 days 15 hours ago

Transgene makes available the 2024 Universal Registration Document

AMF Social Responsibility Immunotherapy Registration Document Transgene
PRESS RELEASE

published on 04/10/2025 at 20:15, 6 days 15 hours ago

Availability of Transgene’s 2024 Universal Registration Document (URD)
Transgene announces availability of its 2024 Universal Registration Document (URD) containing financial reports and ESG factors. French & English versions can be accessed online

Financial Reports Transgene ESG Factors 2024 Universal Registration Document French Version
BRIEF

published on 03/27/2025 at 17:50, 20 days 18 hours ago

Transgene: major advances and outlook for 2025

Immunotherapy Head And Neck Cancer 2024 Financial Results TG4050 Vaccine Myvac® Platform
PRESS RELEASE

published on 03/27/2025 at 17:45, 20 days 18 hours ago

Transgene Achieves Key Milestones in 2024, Including Clinical Proof of Principle for Individualized Cancer Vaccine ? Strong Outlook for 2025
Transgene achieves key milestones in 2024, including clinical proof of principle for individualized cancer vaccine TG4050, with strong outlook for 2025. New trial planned in Q4 2025 for a second indication

Milestones Cancer Vaccine Transgene 2025 Outlook Clinical Proof
BRIEF

published on 01/21/2025 at 17:50, 2 months 26 days ago

Transgene Prepares for Biomed Investor Forum

Investors BIOMED Forum Immunotherapy Transgene Viral Vectors
PRESS RELEASE

published on 01/21/2025 at 17:45, 2 months 26 days ago

Transgene to Participate in the Biomed Forum Investor Conference
Transgene's management team to participate in the Biomed Forum Investor Conference in Paris on February 4, 2025

Investor Conference Paris BIOMED Forum Transgene February 4
BRIEF

published on 11/05/2024 at 07:35, 5 months 12 days ago

Transgene and ProBioGen join forces for personalized cancer vaccines

Biotechnology Cancer Transgene ProBioGen Personalized Vaccines
PRESS RELEASE

published on 10/14/2024 at 07:30, 6 months 3 days ago

Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers
BRIEF

published on 09/14/2024 at 09:10, 7 months 3 days ago

Transgene and BioInvent: promising results for the oncolytic virus BT-001

Cancer Transgene Oncolytic Virus BioInvent BT-001
PRESS RELEASE

published on 09/14/2024 at 09:05, 7 months 3 days ago

Transgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments
Transgene and BioInvent present promising early results of oncolytic virus BT-001 in ESMO 2024, showing antitumor activity in solid tumors. BT-001 induces tumor regression and enhances T cell infiltration

Transgene Oncolytic Virus BioInvent Antitumor Activity ESMO 2024

Published on 04/17/2025 at 01:30, 10 hours 32 minutes ago

Onco-Innovations Announces Private Placement
Published on 04/16/2025 at 23:30, 12 hours 32 minutes ago

Centenario Announces Non-Brokered Private Placement
Published on 04/16/2025 at 22:05, 13 hours 57 minutes ago

Protagonist Therapeutics Reports Granting of Inducement Award
Published on 04/16/2025 at 22:05, 13 hours 57 minutes ago

Southern Energy Announces Listing of Warrants
Published on 04/16/2025 at 22:00, 14 hours 2 minutes ago

Arras Minerals Commences 2025 Exploration Field Program In Kazakhstan

View all ACCESSWIRE

Published on 04/17/2025 at 11:47, 14 minutes ago

Amundi Physical Metals plc: UK Final Terms
Published on 04/17/2025 at 11:41, 20 minutes ago

Amundi Physical Metals plc: Final Terms
Published on 04/17/2025 at 11:00, 1 hour 2 minutes ago

Sylvio Eichhorst becomes the New Chief Financial Officer at BIKE24
Published on 04/17/2025 at 10:54, 1 hour 7 minutes ago

Circus SE Secures European Patent Grant for Core Technology of its AI-Robot
Published on 04/17/2025 at 10:45, 1 hour 16 minutes ago

Deutsche Rohstoff AG: Successful tap issue of the corporate bond by EUR 40 million

View all EQS

Published on 04/17/2025 at 07:01, 5 hours 1 minute ago

bioMérieux – First-Quarter 2025 Business Review
Published on 04/16/2025 at 19:34, 16 hours 27 minutes ago

SFPI GROUP: publication of 2024 annual results
Published on 04/16/2025 at 18:42, 17 hours 19 minutes ago

Deezer unveils new features to offer music fans an even more personalized experience
Published on 04/16/2025 at 18:08, 17 hours 53 minutes ago

ICADE – PR – RESULTS AS OF MARCH 31 2025
Published on 04/16/2025 at 18:00, 18 hours 2 minutes ago

CIS : 2024 annual results

View all LES ECHOS COMFI WIRE

News